Al­ny­lam spells out its APOL­LO-B win for patisir­an — but just how good is it?

Al­ny­lam has de­tailed pos­i­tive APOL­LO-B da­ta for its piv­otal tri­al of patisir­an in treat­ing transthyretin-me­di­at­ed — or AT­TR — amy­loi­do­sis with car­diomy­opa­thy. And the re­sults spell out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER